- Mohs micrographic surgery (MMS) achieves superior cure rates for skin cancer in high-risk locations — 96.1% for facial BCC at 10 years (vs. 95.0% for standard excision) with dramatically better cosmetic outcomes
- Any skin cancer in NCCN Area H warrants Mohs referral — the central face, eyelids, ears, lips, and hands are anatomically critical; standard excision may sacrifice function and cosmesis
- Mohs examines 100% of surgical margins intraoperatively versus 1–2% with standard excision — this complete margin assessment prevents recurrence and eliminates the guesswork of predetermined margins
- Recurrent and incompletely excised tumors demand Mohs regardless of size — failed prior treatments signal more aggressive biology and higher risk of deeper extension
- Aggressive histologic subtypes require Mohs — morpheaform BCC, basosquamous BCC (metatypical BCC, NOT an SCC variant), and poorly differentiated SCC demand the highest-cure-rate technique
- Immunosuppressed patients have 65–250 times higher SCC risk and more aggressive tumors — Mohs offers both superior cure rates and tissue-sparing outcomes when cancer occurs
- Positive margins after standard excision warrant Mohs referral or careful re-excision with wider margins — do not repeat inadequate surgery; Mohs is preferred for facial and high-risk locations
Evidence Snapshot
| Key Finding | Data | Source |
|---|---|---|
| 10-Year Cure Rate: Mohs vs. Standard Excision (Facial BCC) | 96.1% vs 95.0% | van Loo et al., 2014 |
| 5-Year Cure Rate: Mohs vs. Standard Excision (Meta-analysis) | 99% vs 88–92% | Rowe et al., 1989 |
| Recurrent BCC: Mohs Cure Rate at 5 Years | 94.4% | Rowe et al., 1989 |
| Recurrent BCC: Standard Excision Cure Rate at 5 Years | 82.6% | Rowe et al., 1989 |
| Margin Examination: Mohs vs. Standard Excision | 100% vs 1–2% | Clinical standard |
| Immunosuppressed SCC Risk (Transplant Recipients) | 65–250× higher than general population | Euvrard et al., 2003; Hartevelt et al., 1990 |
| NCCN Appropriate Use Criteria for Mohs | H-zone location, high-risk histology, recurrence | Connolly et al., 2012 |
What Is Mohs Micrographic Surgery?
Mohs micrographic surgery is a tissue-sparing surgical technique that achieves high cure rates while preserving healthy tissue. Unlike traditional surgical excision—which removes a predetermined margin and then assesses histology days later—Mohs examines 100% of the surgical margins under the microscope in real-time, allowing the surgeon to remove cancer completely while maximizing tissue preservation.
The procedure is particularly valuable in cosmetically and functionally sensitive areas where tissue conservation is paramount and even small amounts of unnecessary tissue loss can compromise appearance or function.
When Should You Refer for Mohs Surgery?
Is the Tumor Located in NCCN Area H (High-Risk Anatomic Sites)?
The NCCN Area H (also called the "H-zone" or anatomically high-risk areas) includes sites where tissue conservation is critical:
- Central face: nose, medial cheeks, glabella, forehead above the brows
- Periocular region: eyelids, eyebrows, medial and lateral canthi
- Perioral/lips: lips, oral commissure, chin
- Ears and periauricular areas: including postauricular skin, retroauricular folds
- Hands, feet, ankles, nail units
- Genitalia, nipples, areola
Note: The "H-zone" gets its name from the classic distribution pattern (H-shaped), but NCCN Area H is the current standard nomenclature. Lateral cheeks and forehead (outside the medial brow region) are Zone 2 (intermediate-risk), not Area H, and may be managed with standard excision if tumors are small and low-risk (Connolly et al., 2012).
Bottom Line: Any BCC or SCC in NCCN Area H, regardless of size or histology, should be considered for Mohs referral. Even small tumors in these areas benefit from Mohs because standard excision may result in significant cosmetic or functional compromise. A 5 mm BCC on the nose is a better Mohs candidate than a 2 cm BCC on the chest wall, because location and tissue conservation matter more than size alone.
The periorbital area (around the eyes) is one of the most cosmetically sensitive regions on the face. Standard surgical excision with predetermined 4–5 mm margins can result in significant tissue loss and eyelid malposition. Mohs surgery, by removing only tumor-bearing tissue, can spare 5–10 mm of healthy tissue compared to standard excision—a difference that can prevent eyelid retraction or functional problems.
Has the Tumor Been Incompletely Excised or Recurred?
Recurrent tumors are biologically different from primary lesions. They are often more aggressive and tend to extend further clinically and subclinically than primary tumors (Rowe et al., 1989).
Key Data:
- Mohs surgery on recurrent BCC: 94.4% cure rate at 5 years
- Standard excision on recurrent BCC: 82.6% cure rate at 5 years
- Recurrence rate after Mohs: 0–5.6% (depending on tumor type)
- Recurrence rate after standard excision on recurrent tumors: 10–23%
If you have already excised a BCC or SCC and histology shows positive margins (tumor present at the edge), refer immediately for Mohs. Do not attempt re-excision under local anesthesia in the clinic with predetermined wider margins—this approach carries unacceptably high recurrence risk. Either Mohs surgery or formal re-excision with wider margins in the OR setting (planned closure, full hemostasis, proper layer reconstruction) is appropriate, but Mohs is preferred because it allows real-time margin assessment and minimizes unnecessary tissue removal.
Is the Tumor Larger Than Recommended Size Thresholds?
Size alone is not an indication for Mohs, but when combined with other factors, it increases the likelihood of subclinical extension.
Size Thresholds by Location:
| Location | Size for Mohs Consideration | Notes |
|---|---|---|
| NCCN Area H (face, ears, lips, hands) | >0.6–1 cm diameter | Mohs preferred even for smaller tumors if high-risk features present |
| Trunk/Extremities (low-risk areas) | >2 cm diameter | Size more important here; location is lower-risk |
| Aggressive histology | Any size in Area H | Morpheaform, basosquamous BCC, poorly differentiated SCC warrant Mohs regardless of size |
Clinical Pearl: A 5 mm BCC on the nose is a better Mohs candidate than a 2 cm well-differentiated BCC on the chest, because location and tissue conservation matter more than size alone.
Does the Tumor Have Aggressive Histologic Features?
Histologic subtype is a critical predictor of behavior and recurrence risk.
High-Risk Histologic Subtypes (BCC):
| Subtype | Risk Profile | Why? |
|---|---|---|
| Morpheaform/Sclerodermiform | Highest | Infiltrative borders that extend far beyond clinically visible margins; difficult to assess completely with standard excision |
| Micronodular | High | Small islands of tumor extending well beyond clinical borders |
| Basosquamous (Metatypical BCC) | High | This is a BCC variant with squamous differentiation, NOT an SCC. More aggressive histology, higher recurrence and metastatic potential than pure BCC |
| Infiltrating | High | Undefined borders, high subclinical extension |
SCC Subtypes:
| Subtype | Risk Profile | Why? |
|---|---|---|
| Well-differentiated SCC | Low-intermediate | Generally predictable behavior, lower metastatic risk |
| Moderately differentiated SCC | Intermediate | Higher risk than well-differentiated; requires assessment for other high-risk features |
| Poorly differentiated / Undifferentiated SCC | High | Higher recurrence, greater metastatic potential (29% risk of nodal metastasis vs. 3% for well-differentiated) |
| Spindle cell SCC | High | Aggressive variant with higher metastatic potential |
| Sarcomatoid SCC | High | Aggressive; may be associated with deep invasion |
Bottom Line: If your pathology report describes morpheaform, infiltrating, micronodular, basosquamous, or poorly differentiated features, refer for Mohs, especially if the tumor is on the face or in NCCN Area H.
Is There Perineural Involvement?
Perineural invasion (PNI) is a poor prognostic sign and warrants Mohs referral.
What to Look For:
- Pathology report mentions "perineural invasion," "perineural involvement," "nerve sheath invasion," or "desmoplasia"
- Patient describes pain, numbness, tingling, or nerve-like symptoms near the tumor
- Tumor appears to track along a nerve distribution
Clinical Significance: Tumors with perineural invasion often extend much further than clinically evident. Mohs micrographic surgery allows intraoperative assessment of nerve involvement and aggressive margin control, making it the ideal technique for PNI-positive tumors.
Is the Patient Immunosuppressed?
Immunocompromised patients carry substantially higher risk for aggressive skin cancer, particularly squamous cell carcinoma.
Risk Groups:
- Solid organ transplant recipients (highest risk)
- Chronic lymphocytic leukemia
- HIV+ patients with CD4 <200 cells/mm³
- Patients on long-term pharmacologic immunosuppression (biologics, JAK inhibitors, TNF-alpha inhibitors, etc.)
Clinical Behavior in Immunosuppressed Patients:
- SCCs are 65–250 times more common in transplant recipients than the general population (varies by organ type, immunosuppressive regimen, and time since transplant)
- Tumors behave more aggressively, with higher rates of desmoplasia, perineural invasion, and metastatic potential
- Multiple and recurrent cancers are the norm, not the exception
- Immunosuppressed SCCs have a 20–35% rate of lymph node metastasis versus 2–5% in immunocompetent patients
Mohs Surgery Rationale: Mohs offers superior cure rates, tissue conservation (critical given the high disease burden), and real-time identification of aggressive features. While postoperative complication rates are slightly higher in immunosuppressed patients due to delayed wound healing and infection risk, the benefits generally outweigh risks.
Transplant recipients who develop skin cancer face a fundamentally different disease. A "small" 1cm SCC in a transplant patient has the biological behavior of a large or high-risk tumor in an immunocompetent person. Mohs is not just recommended—it is often necessary for adequate outcomes. — Dr. Hocker
Bottom Line: Consider Mohs for immunosuppressed patients with any SCC. For BCCs in immunosuppressed patients, use Mohs if the tumor is in Area H or has high-risk features; aggressive surveillance every 3–6 months is mandatory regardless of treatment choice.
Other High-Risk Features
Additional circumstances favoring Mohs referral:
- Prior radiation therapy to the area (increases risk of aggressive tumor behavior and recurrence)
- Genetic syndromes: Basal cell nevus syndrome (BCNS/Gorlin syndrome—caused by PTCH1 mutations on chromosome 9, NOT BRCA1), xeroderma pigmentosum
- Rapidly growing tumors or tumors causing pain, numbness, or tingling (possible perineural invasion)
- Ill-defined clinical borders (difficult to assess extent clinically; suggests subclinical extension)
- Tumors in or near critical structures (eyes, nose, ears, lips, genitalia)
- Patient preference for tissue conservation in cosmetically or functionally sensitive areas
If a patient has a personal or family history of multiple skin cancers, birthmarks, jaw cysts, skeletal abnormalities, or central nervous system tumors, ask about Gorlin syndrome (basal cell nevus syndrome). BCNS is caused by mutations in the PTCH1 gene (not BRCA1) and predisposes to hundreds of BCCs over a lifetime. Patients with BCNS require aggressive surveillance and may benefit from systemic therapies (vismodegib, sonidegib) in addition to surgical management. Every patient with Gorlin syndrome should be managed by a Mohs surgeon experienced with this syndrome.
When Is Standard Excision Sufficient?
Not every skin cancer needs Mohs surgery. Standard surgical excision with predetermined margins and delayed histologic assessment is appropriate for:
- Small, well-defined primary tumors (<0.5 cm) on trunk or extremities with well-differentiated histology
- Well-differentiated SCC without perineural invasion, immunosuppression, or other high-risk features
- Superficial BCCs (non-aggressive subtypes) on low-risk areas (trunk, extremities)
- Immunocompetent patients with primary, low-risk tumors in low-risk locations
Important Clinical Note: For standard excision margins in low-risk cases:
- BCC: NCCN recommends 4 mm margins (not 4–5 mm)
- Low-risk SCC: 6 mm margins for primary tumors
- High-risk SCC: Mohs is preferred; if standard excision used, 10+ mm margins required and careful follow-up mandatory
If positive margins result: If you perform standard excision and margins come back positive, refer for Mohs or perform formal re-excision with wider margins (>4–5 mm for BCC, 10+ mm for SCC) in the operating room with proper planning and closure technique. Do not attempt simple re-excision under local anesthesia in the clinic, as inadequate re-excision leads to higher recurrence.
Comparison: Mohs vs. Standard Excision vs. Radiation
| Factor | Mohs Micrographic Surgery | Standard Surgical Excision | Radiation Therapy |
|---|---|---|---|
| Margin Assessment | 100% of margins intraoperative | 1–2% of margins examined | None |
| Tissue Preservation | Maximal (only tumor-bearing tissue removed) | Predetermined, often excessive | Variable by dose/fractionation |
| Cure Rate (Primary BCC, 10-year) | 96.1% | 95.0% | 85–90% |
| Cure Rate (Primary BCC, 5-year meta-analysis) | 99% | 88–92% | 85–90% |
| Cure Rate (Recurrent BCC, 5-year) | 94.4% | 82.6% | Variable |
| Cure Rate (SCC) | 92–97% | 85–92% | 80–90% |
| Treatment Duration | Single day (usually 2–4 hours) | Single day | 5–6 weeks |
| Cosmetic Outcome | Excellent (less tissue removed) | Good–Excellent | Fair–Good (sclerosis, atrophy) |
| Cost | Higher per procedure | Lower | Lower |
| Best For | Area H, recurrent, aggressive, perineural invasion | Low-risk trunk/extremities | Poor surgical candidates, elderly, inoperable |
| Downtime | Minimal | Minimal | None during treatment |
Data Sources: Rowe et al. 1989 (5-year BCC); van Loo et al. 2014 (10-year BCC); Smeets et al. 2004 (5-year SCC); Connolly et al. 2012 (NCCN Appropriate Use)
What Information Should You Include in a Mohs Referral?
A complete referral sets the stage for optimal outcomes. Include:
Original pathology report (if available)
- Histologic type and subtype
- Size
- Depth of invasion
- Margins (positive, negative, or involved)
- Perineural invasion or desmoplasia
- Differentiation level (for SCC)
Precise anatomic location
- Include a photograph or sketch with measurements from nearby anatomic landmarks
- Note proximity to eyes, mouth, nerves, or other critical structures
- Specify if on eyelid margin, medial canthus, lip vermillion, etc.
Clinical description
- Size, color, borders
- Duration and growth rate
- Symptoms (pain, numbness, bleeding, ulceration)
- Any prior biopsy location
Relevant medical history
- Immunosuppression status (organ transplant, immunosuppressive medications, HIV status)
- Prior radiation therapy to the area
- Prior skin cancers (number, locations, treatments)
- Genetic syndromes (Gorlin syndrome, xeroderma pigmentosum)
Patient goals and constraints
- Cosmetic concerns
- Functional concerns (eyelid function, mouth opening, hand dexterity)
- Availability for staged procedures if needed
- Preference for single-session treatment
Pro Tip: A clear, high-quality photograph taken at adequate magnification is invaluable. It helps the Mohs surgeon identify the exact lesion, assess clinical borders more accurately, and plan the case preoperatively.
When to Refer for Mohs Micrographic Surgery: The Complete Decision Guide
4 game modes to test what you've learned. Pick your style.
Choose your mode
Take your time. Get detailed explanations after each question.
15-second timer. Score points for speed. Build streaks for multipliers.
Pick your category. Pick your value. How much do you know?
Progressive difficulty. 3 lifelines. How far can you go?
Frequently Asked Questions
1. If I excise a skin cancer and margins are negative, should I still refer for Mohs?
Not necessarily. If you have completely removed a small, low-risk primary tumor using proper technique with adequate margins (typically 4 mm for BCC, 6 mm for low-risk SCC) and it is located on a low-risk area (trunk or extremities), observation is reasonable. However, if the tumor is in NCCN Area H or has high-risk features (poor differentiation, perineural invasion, size >1 cm), Mohs would have been the better initial choice, and patients should know this.
2. What does "positive margins" mean, and why should it trigger a Mohs referral?
Positive margins mean tumor cells are present at the edge of the specimen, indicating incomplete excision. This carries a 15–40% recurrence risk if untreated. Mohs allows definitive removal while preserving additional tissue compared to blind re-excision with larger margins. This is particularly important for facial tumors where each millimeter of tissue matters.
3. Are there any contraindications to Mohs surgery?
Mohs can be safely performed in most patients, including the elderly and immunosuppressed. Relative (not absolute) concerns include severe coagulopathy (but can often be managed with careful hemostasis and postoperative precautions), inability to tolerate local anesthesia, or unreliable follow-up. Age alone is not a contraindication. Patients with pacemakers or certain implantable devices should alert the Mohs surgeon, but these are rarely contraindications.
4. How long does a Mohs procedure take?
Most cases take 2–4 hours, though complex tumors on the face or with aggressive histology may take longer. The exact time depends on how many surgical stages are required (how many layers of tissue must be removed). Simple removal may take 1–2 hours; large or complex tumors may take 4–6 hours or longer.
5. Can I biopsy a suspected skin cancer and then refer to a Mohs surgeon, or should I just refer without biopsy?
Both approaches are reasonable. A diagnostic biopsy provides histologic certainty and helps the Mohs surgeon plan the case (size, histology, depth, margins). However, if you are confident in your clinical diagnosis and the patient agrees, direct referral without biopsy is appropriate. The Mohs surgeon can excise and treat in a single visit, and many prefer this approach to avoid scar contamination from prior biopsy.
6. What is the follow-up after Mohs surgery?
The Mohs surgeon will provide detailed postoperative instructions including wound care, suture removal timing (typically 7–14 days depending on location), and restrictions on activity. Patients should follow up with their dermatologist for long-term surveillance, as skin cancer is a field disease—patients at risk for one cancer are at substantially higher risk for additional cancers. Immunosuppressed patients especially need surveillance every 3–6 months for the first few years.
7. Is Mohs surgery covered by insurance?
Yes, Mohs micrographic surgery is a covered procedure by most insurance plans when appropriate criteria are met (Area H location, recurrent tumor, aggressive histology, high-risk features). Your Mohs surgeon's office can verify coverage and help with prior authorization if needed. Cost varies widely by geography and payer but typically ranges from $2,000–$6,000 depending on tumor complexity.
8. What happens if the Mohs surgeon finds the tumor extends deeply or involves structures like bone or nerve?
If the tumor invades bone, nerve, or other deep structures, the Mohs surgeon will remove all visible tumor and then coordinate with appropriate specialists (otolaryngology, neurosurgery, orthopedic surgery) for management of the deeper disease. This may involve staged procedures, imaging, or systemic therapy depending on the extent and type of deeper involvement. The goal is complete tumor removal while preserving function.
"Location matters more than size. A 5 mm BCC on the nose beats a 2 cm BCC on the trunk as a Mohs candidate."
"Positive margins are a red flag—refer for Mohs, don't just re-excise."
"Immunosuppressed patients with skin cancer have aggressive biology. Lower your threshold for Mohs referral."
"Include the pathology report and a clear photograph in every Mohs referral."
About This Site
Skin Trust is a free educational website created by Dr. Thomas L.H. Hocker, M.D., M.Phil. to make dermatologic knowledge accessible to patients and healthcare professionals. All content is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Skin Trust is Dr. Hocker's independent educational work, completely unaffiliated with any medical practice, healthcare system, hospital, university, or organization. Using this website does not create a doctor-patient relationship. If you have or suspect you have a medical condition, consult a qualified healthcare provider. Never delay seeking professional care based on information from this site.
References
Rowe, D. E., Carroll, R. J., & Day, C. L. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, lip, oral cavity, and oropharynx. Journal of the American Academy of Dermatology. 1989;26(6):976–990. PMID: 2646336
van Loo, E., Mosterd, K., Krekels, G. A., Sommer, A., Nelemans, P. J., & Nieman, F. H. Surgical excision versus Mohs micrographic surgery for basal cell carcinoma of the face: A randomised controlled trial with 10-year follow-up. The Lancet Oncology. 2014;15(12):1367–1376. PMID: 25262378
Smeets, N. W., Kuijpers, D. I., Nelemans, P., Ostertag, J. U., Verhaegh, M. E., Krekels, G. A., & Neumann, M. H. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised controlled trial with 10-year follow-up. The Lancet Oncology. 2004;5(1):25–33. PMID: 14602432
Connolly, S. M., Baker, D. R., Coldiron, B. M., Fazio, M. J., Storrs, P. A., Wiley, E. A., & Barbosa, V. H. AAD/ACMS/ASDSA/ASMS 2012 Appropriate Use Criteria for Mohs Micrographic Surgery. Journal of the American Academy of Dermatology. 2012;67(2):171–193. PMID: 22086049
Euvrard, S., Kanitakis, J., & Claudy, A. Epidemiology of skin cancer in organ transplant recipients. Lancet Oncology. 2003;4(5):270–280. PMID: 12917290
Hartevelt, M. M., Bavinck, J. N., Kootte, A. M., Tjong, A. H., & Vermeer, B. J. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990;49(3):506–509. PMID: 2138382
Karia, P. S., Han, J., & Schmults, C. D. Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States; 2012. Journal of the American Academy of Dermatology. 2013;68(6):957–966. PMID: 23375456
Schmults, C. D., Blitzblau, R. C., Aasi, S. Z., Boland, G. M., Bordeaux, J. S., Carney, P. S., ... & Grossman, R. A. NCCN Guidelines Insights: Squamous Cell Carcinoma of the Skin, Version 2.2021. Journal of the National Comprehensive Cancer Network. 2021;19(5):474–481.
Author: Thomas L.H. Hocker, M.D., M.Phil.
Dr. Hocker is a board-certified dermatologist, dermatopathologist, and Mohs micrographic surgeon. He completed his M.D. at Harvard Medical School, his dermatology residency at Mayo Clinic, and specialized training in dermatopathology and Mohs micrographic surgery. Dr. Hocker is triple board-certified in dermatology, dermatopathology, and Mohs micrographic surgery through the American Board of Dermatology and American Board of Medical Specialties. He has performed over 23,000 Mohs micrographic surgery cases and is Founding Director of Dermatologic Surgery at the University of Missouri-Kansas City School of Medicine.
